A groundbreaking study from the University of Glasgow has revealed that a simple blood test can uncover undiagnosed heart failure in a significant number of people living with diabetes, potentially transforming early detection and treatment strategies across the United Kingdom. The research, part of the TARTAN-HF trial, highlights the hidden prevalence of this serious condition among high-risk diabetic patients and underscores the vital role of accessible screening tools in preventing adverse outcomes.

Heart failure remains a leading cause of hospitalisation and mortality in the UK, particularly among those with diabetes, where cardiovascular complications are markedly elevated. With diabetes affecting over 5.8 million people in the UK—around 4.8 million diagnosed and more than 1 million undiagnosed—this new evidence calls for targeted screening programmes to bridge the diagnostic gap.

The Alarming Link Between Diabetes and Heart Failure

Diabetes mellitus, a chronic condition characterised by elevated blood glucose levels due to insufficient insulin production or ineffective insulin use, significantly heightens the risk of cardiovascular diseases. Type 2 diabetes, accounting for 90% of cases in the UK, shares multiple risk factors with heart failure, including hypertension, obesity, and chronic kidney disease. Heart failure, where the heart cannot pump blood effectively to meet the body's needs, affects over one million people in the UK, with approximately 200,000 new diagnoses annually. Strikingly, an estimated 29% of heart failure patients also have diabetes, rising to 37% among those hospitalised.

Symptoms of heart failure, such as fatigue, shortness of breath, and swelling in the legs, often overlap with those of diabetes or are dismissed as age-related, leading to underdiagnosis. Preserved ejection fraction heart failure (HFpEF), where the heart's pumping strength appears normal but stiffness impairs filling, is especially elusive without specific testing. Diabetics are two to four times more likely to develop HFpEF, making proactive screening essential.

University of Glasgow's Leadership in Cardiovascular Research

The University of Glasgow, a powerhouse in UK higher education, hosts the School of Cardiovascular & Metabolic Health, renowned for pioneering work in heart failure, diabetes, and metabolic disorders. This school integrates clinical trials, basic science, and population studies to address pressing health challenges. Researchers like Professor Mark Petrie and Dr Kieran Docherty have built international reputations through rigorous investigations into heart failure therapies and risk stratification.

Glasgow's contributions extend beyond this trial; the institution has led landmark studies on SGLT2 inhibitors—medications originally for diabetes that now revolutionise heart failure management by reducing hospitalisations by up to 30%. Such research positions UK universities at the forefront of translating discoveries into NHS practice, fostering collaborations with industry like AstraZeneca and Roche Diagnostics.

Decoding the TARTAN-HF Trial: Design and Execution

The TARTAN-HF (Targeted Screening for Undiagnosed Heart Failure) trial was a multi-centre, randomised controlled trial launched over three years ago, recruiting more than 700 participants from NHS Greater Glasgow & Clyde and NHS Lanarkshire. Eligible patients had type 1 or type 2 diabetes plus at least one additional heart failure risk factor, such as prior myocardial infarction, chronic kidney disease, or atrial fibrillation.

Participants were randomised 1:1 to intervention (screening) or control (usual care). The screening pathway began with a venous blood draw to measure N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker released by strained heart muscle cells. Levels above predefined thresholds prompted automated referrals for transthoracic echocardiography—a non-invasive ultrasound assessing heart structure and function. Diagnoses were confirmed per European Society of Cardiology guidelines, with follow-up at six months tracking new diagnoses, treatment changes, and clinical events.

• Recruitment: Over 700 high-risk diabetics.
• Screening tools: NT-proBNP blood test + selective echocardiography.
• Primary outcome: New heart failure diagnosis within six months.
• Secondary outcomes: Treatment initiation, hospitalisations, mortality.

Groundbreaking Results: 25% Detection Rate

The trial's findings, unveiled at the American College of Cardiology's 2026 Scientific Session in New Orleans, were staggering. In the screening arm, 24.9% of participants received a new heart failure diagnosis within six months, compared to just 1% in the usual care group. Nearly all cases were HFpEF, underscoring the test's sensitivity for this subtype.

Screened patients saw a marked uptick in guideline-directed medical therapy: sodium-glucose cotransporter-2 inhibitor (SGLT2i) use rose from 24% to 39%. Critically, the intervention group experienced a 55% relative reduction in heart failure hospitalisation or cardiovascular death (3.1% event rate vs. 6.8%). These outcomes demonstrate not just detection, but actionable impact on prognosis.

Photo by Johnny Briggs on Unsplash

Understanding NT-proBNP: The Game-Changing Biomarker

NT-proBNP (N-terminal prohormone of brain natriuretic peptide) is produced by the heart's ventricles in response to wall stress from volume or pressure overload. In healthy individuals, levels are low (<125 pg/mL for under 75s); elevations signal pathology. The test is inexpensive, rapid (results in minutes via point-of-care devices), and widely available in UK GP practices and hospitals.

In diabetics, NT-proBNP retains strong prognostic value despite potential confounders like obesity or renal impairment. Thresholds in TARTAN-HF were optimised for high-risk groups: typically >300 pg/mL prompts imaging. For deeper insight, visit the University of Glasgow's announcement.

Step-by-step process:

• Draw blood (simple venepuncture).
• Lab or POC analysis (under 20 minutes).
• Interpret: Elevated → echo referral.
• Diagnose and treat promptly.

Transformative Treatment Pathways Opened by Early Detection

Early diagnosis enables initiation of quadruple therapy for heart failure: SGLT2i (e.g., dapagliflozin), angiotensin receptor-neprilysin inhibitors (ARNI like sacubitril/valsartan), mineralocorticoid receptor antagonists (MRAs), and beta-blockers. SGLT2i, proven in trials like DAPA-HF and EMPEROR-Reduced, slash HF risks by 25-30% in diabetics, acting via natriuresis, reduced inflammation, and metabolic shifts.

TARTAN-HF's 55% event reduction aligns with real-world data, suggesting screening could avert thousands of admissions yearly. For UK context, with 820,000 on GP heart failure registers, scaling this could save NHS millions while improving quality-adjusted life years.

Insights from Glasgow's Leading Researchers

Dr Kieran Docherty, Clinical Senior Lecturer, emphasised: "Our results show we identified heart failure in a large proportion of people with diabetes... The strategy is simple and easy-to-implement." Professor Mark Petrie added: "Screening could significantly benefit people with diabetes... Further trials in other regions would be beneficial."

Industry partners echoed: Dr Edward Piper (AstraZeneca) noted targeted screening identifies one in four high-risk cases; Dr Christian Simon (Roche) praised NT-proBNP's transformative power. These voices highlight interdisciplinary synergy driving UK research excellence.

Implications for the NHS and UK Public Health

Implementing TARTAN-HF-style screening in primary care could address diagnostic delays, where only 50% of HF cases are recognised pre-hospitalisation. With diabetes driving one in ten CVD deaths, integration into annual reviews (via NHS Diabetes Prevention Programme) is feasible. Cost-effectiveness: NT-proBNP (~£5-10/test) vs. averting £10,000+ per HF admission.

Explore NHS implications further in The Independent's coverage. Regional rollout in Scotland, via NHS Greater Glasgow & Clyde, could pioneer national policy.

Future Horizons: Expanding Screening and Research

Researchers advocate larger, diverse trials to validate across ethnicities and regions. Extending to atrial fibrillation or valvular disease screening using similar biomarkers holds promise. Glasgow plans longitudinal studies tracking screened cohorts, potentially informing NICE guidelines.

In UK higher education, this exemplifies translational research: from lab to clinic, boosting funding via UKRI and BHF. For academics, opportunities abound in cardio-metabolic trials amid rising prevalence.

Photo by Johnny Briggs on Unsplash

Glasgow's Role in Shaping Global Heart Health Research

As a Russell Group university, Glasgow exemplifies UK higher education's impact, with spin-outs like Us2.ai advancing AI echocardiography. This trial reinforces Scotland's cardio research hub status, attracting talent and investment. For aspiring researchers, Glasgow offers PhD programmes in heart failure biomarkers, bridging diabetes and cardiology.

The TARTAN-HF success story illustrates how university-led innovation can alleviate NHS burdens, save lives, and advance knowledge—one blood test at a time.